Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

2(33.3%)

6Total

Phase 2(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07020923Phase 2Active Not Recruiting

Monthly Dosing of Atacicept in IgAN

Role: lead

NCT06983028Phase 2Recruiting

Atacicept in Multiple Glomerular Diseases

Role: lead

NCT04716231Phase 3Active Not Recruiting

Atacicept in Subjects With IgA Nephropathy

Role: lead

NCT05609812Phase 3Withdrawn

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

Role: lead

NCT06674577Phase 2Enrolling By Invitation

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Role: lead

NCT04294472Phase 2Completed

A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients

Role: lead

All 6 trials loaded